- Head, Solid Tumor Section, Director, Aftercare Program, Division of Haematology/Oncology
- MD, M.Sc., FRCPC
- REACH Profile:
- Paul Nathan's REACH profile
- U of T Positions:
- Professor, Departments of Paediatrics and Healthy Policy, Management & Evaluation
Director, Aftercare Program
Division of Haematology/Oncology
Senior Associate Scientist
Child Health Evaluative Sciences
Dr. Paul Nathan is Director of the Aftercare clinic in the Division of Paediatric Hematology/Oncology and a Senior Associate Scientist in the Research Institute at The Hospital for Sick Children. He is a Professor of Paediatrics and Health Policy, Management and Evaluation at the University of Toronto. His research is focused on health care utilization by adult survivors of childhood cancer, as well as specific “late effects” of cancer therapy, including cardiac disease and second malignant neoplasms. He is a member of several North American research and clinical committees focused on research, clinical care, and policy creation for long-term survivors of childhood cancer.
Dr. Nathan’s clinical practice and research program is focused on survivors of childhood cancer. His research addresses specific "late effects" of cancer therapy (such as cardiac disease) as well as healthcare utilization and screening for complications in survivors. He is a member of the steering committees of the Children’s Oncology Group (COG) Survivorship and Outcomes Committee, and the Childhood Cancer Survivor Study (CCSS).
Education and experience
- 1991–1995: MD, University of Toronto, Toronto, Ontario
- 1995–1999: Resident (Chief Resident: 1998-99), Paediatrics, The Hospital for Sick Children, Toronto, Ontario
- 1999–2001: Fellow (Chief Fellow: 2000-01), Paediatric Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario
- 2001–2003: Clinical Research Fellow, Paediatric Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario
- 2001–2003: M.Sc., Clinical Health Sciences, Health Research Methodology, McMaster University, Hamilton, Ontario
2003–2004: Fellowship, Advanced Studies Program in Pediatric Oncology, National Cancer Institute, Pediatric Oncology Branch, Bethesda, Maryland
- 2014: Manuscript Award Best Oncology Paper of 2013 (Research Award), Gudas Award - American Physiotherapy Association
Manuscript, “A Comprehensive Healthy Lifestyle Program for Children Receiving Treatment for Acute Lymphoblastic Leukemia: Feasibility and Preliminary Efficacy Data”
- 2010: Manuscript Award, American Society of Clinical Oncology (ASCO) (Research Award)
Manuscript, “Cancer Screening in Adult Survivors of Childhood Cancer” chosen as one of the major research advances in cancer treatment, prevention and screening in 2009
- 2008: Manuscript Award, American Society of Clinical Oncology (ASCO) (Research Award)
Manuscript, “Risk Based Care in Survivors of Childhood Cancer” chosen as one of the major research advances in cancer treatment, prevention and screening in 2007
- Yan AP, Chen Y, Henderson TO, Oeffinger KC, Hudson MM, Gibson TM, Neglia JP, Leisenring WM, Ness KK, Ford JS, Robinson LL, Armstrong GT, Yasui Y, Nathan PC. Adherence to surveillance for second malignant neoplasms and cardiac dysfunction in childhood cancer survivors: A Childhood Cancer Survivor study. Journal of Clinical Oncology. May 2020;38(15):1711-1722.
- Khanna A, Pequeno P, Gupta S, Thavendiranathan P, Lee DS, Abdel-Qadir H, Nathan PC. Increased risk of all cardiovascular disease subtypes among childhood cancer survivors: A population-based matched cohort study. Circulation. 2019 Sept;140(12):1041-1043.
- Gupta S, Pole JD, Baxter NN, Sutradhar R, Lau C, Nagamuthu C, Nathan PC. The effect of adopting pediatric protocols on outcomes in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: An IMPACT Cohort study. Cancer Medicine. 2019 May;8(5):2095-2103.
- Nathan PC, Henderson TO, Kirchhoff AC, Park ER, Yabroff KR. Financial hardship, and the economic effect of childhood cancer survivorship. Journal of Clinical Oncology. 2018 Jul;36(21):2198-2205.
- Nathan PC, Bremner KE, Liu N, Gupta S, Greenberg ML, McBride ML, Krahn MD, de Oliveira C. Resource utilization and costs in adolescents treated for cancer in pediatric vs adult institutions. Journal of the National Cancer Institute. 2019 Mar;111(3):322-330.
- 2018–2025: Principal Investigator. Optimizing outcomes in survivors of childhood, adolescent and young adult cancer. Canadian Institutes of Health Research (CIHR) – Foundation Grant. PI: Nathan P. Co-investigators: Armstrong A, Barwick M, Baxter N, Goudie C, Greenberg M, Grimshaw J, Grundy P, Gupta S, Ivers N, Hodgson D, Hudson M, Krahn M, Kremer L, Malkin D, Manlhiot C, Mital S, Pechlivanoglou P, Pole J, Stinson J, Sutradhar R, Taccone M, Whitlock J, Yasui Y, Yuan Y. $2,729,448 CAD
- 2018–2021: Co-Principal Investigator. The risk for premature atherosclerosis in survivors of childhood cancer: A study in the Preventing Cardiac Sequelae in Pediatric Cancer Survivors (PCS2) cohort. Canadian Institutes of Health Research (CIHR) – Project Grant. Co-PIs: Mertens L, Nathan P. Co-investigators: Adeli K, Friedberg MK, Hodgson DC, Manlhiot C, McCrindle BW. $554,625 CAD
- 2020–2021: Co-Investigator. Design and evaluation of a system-wide surveillance system for late effects of treatment in childhood cancer survivors. CIHR – Priority Announcement for Patient-Oriented Research. PI: Ivers N. Co-Investigators: Nathan P, Baxter N, Grimshaw J, Gupta S, Heisey R, Hodson D, Lofters A, Moody L, Presseau J, Taccone M, Taljaard M, Thavorn K. $100,000 CAD.
- 2018–2020: Principal Investigator. Performance and cost-effectiveness of a prediction tool to identify cancer predisposition syndromes in children with cancer. Cancer Research Society Operating Grant. PI: Nathan P. Co-investigators: Goudie C, Pechlivanoglou P, Villani A, Malkin D, Hodgson D, Dendkuri N, Pole J, Cullinan N. $120,000 CAD
- 2014–2019: Co-Principal Investigator. Initiative to maximize progress in adolescent and young adult (AYA) cancer therapy (IMPACT). Canadian Institutes for Health Research (CIHR). Co-PIs: Nathan P, Baxter N. Co-investigators: Barr R, Gupta S, Sawka A, Wasserman J, Greenberg M, Pole J, Sussman J, Gupta A, Rapoport A, Sutradhar R. $913,872 CAD